X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DISHMAN PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DISHMAN PHARMA SANOFI INDIA/
DISHMAN PHARMA
 
P/E (TTM) x 32.9 25.1 131.3% View Chart
P/BV x 6.3 3.3 187.5% View Chart
Dividend Yield % 1.4 0.7 216.5%  

Financials

 SANOFI INDIA   DISHMAN PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
DISHMAN PHARMA
Mar-16
SANOFI INDIA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs4,560374 1,217.9%   
Low Rs4,400129 3,413.5%   
Sales per share (Unadj.) Rs1,028.5197.8 520.0%  
Earnings per share (Unadj.) Rs129.021.2 608.1%  
Cash flow per share (Unadj.) Rs186.034.7 535.6%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.8 191.0%  
Book value per share (Unadj.) Rs753.6179.9 418.9%  
Shares outstanding (eoy) m23.0380.69 28.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.3 342.4%   
Avg P/E ratio x34.711.9 292.7%  
P/CF ratio (eoy) x24.17.2 332.4%  
Price / Book Value ratio x5.91.4 424.9%  
Dividend payout %52.79.4 559.1%   
Avg Mkt Cap Rs m103,17420,306 508.1%   
No. of employees `0003.60.8 437.0%   
Total wages/salary Rs m3,5925,355 67.1%   
Avg. sales/employee Rs Th6,537.719,252.7 34.0%   
Avg. wages/employee Rs Th991.46,459.5 15.3%   
Avg. net profit/employee Rs Th819.82,064.1 39.7%   
INCOME DATA
Net Sales Rs m23,68615,961 148.4%  
Other income Rs m708265 266.8%   
Total revenues Rs m24,39416,226 150.3%   
Gross profit Rs m5,2814,103 128.7%  
Depreciation Rs m1,3131,091 120.4%   
Interest Rs m15944 1.6%   
Profit before tax Rs m4,6612,334 199.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691624 271.2%   
Profit after tax Rs m2,9701,711 173.6%  
Gross profit margin %22.325.7 86.7%  
Effective tax rate %36.326.7 135.8%   
Net profit margin %12.510.7 117.0%  
BALANCE SHEET DATA
Current assets Rs m15,67311,018 142.3%   
Current liabilities Rs m6,6789,517 70.2%   
Net working cap to sales %38.09.4 403.8%  
Current ratio x2.31.2 202.7%  
Inventory Days Days76110 68.8%  
Debtors Days Days2235 64.1%  
Net fixed assets Rs m8,09816,304 49.7%   
Share capital Rs m230161 142.7%   
"Free" reserves Rs m17,08812,907 132.4%   
Net worth Rs m17,35614,516 119.6%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m25,40029,805 85.2%  
Interest coverage x311.73.5 8,981.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.5 174.1%   
Return on assets %11.88.9 131.9%  
Return on equity %17.111.8 145.2%  
Return on capital %26.917.5 153.7%  
Exports to sales %24.524.8 98.8%   
Imports to sales %28.03.7 748.9%   
Exports (fob) Rs m5,8013,956 146.6%   
Imports (cif) Rs m6,627596 1,111.4%   
Fx inflow Rs m7,1454,952 144.3%   
Fx outflow Rs m6,846697 982.5%   
Net fx Rs m2994,255 7.0%   
CASH FLOW
From Operations Rs m3,2262,786 115.8%  
From Investments Rs m-1,555-1,529 101.7%  
From Financial Activity Rs m-1,818-941 193.2%  
Net Cashflow Rs m-147316 -46.5%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 3.7 389.2%  
FIIs % 14.6 12.7 115.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 22.1 47.5%  
Shareholders   15,184 46,261 32.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jan 19, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - DR. DATSONS LABS COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS